Hajduk Split prospect Branimir Mlacic is a target for Inter Milan. An agreement over the teen is already close to being struck. Inter aim to sign Mlacic in January and leave him with Hajduk Split ...

About Real Estate Split Corp. Real Estate Split Corp. invests in a diversified, actively managed portfolio of dividend-paying securities of issuers operating in the real estate or related sectors. Its ...

Biliary tract cancers, including intrahepatic, perihilar, and extrahepatic cholangiocarcinoma and gallbladder cancer, are among the most aggressive gastrointestinal malignancies. Treatment options ...

And just this past week against Pittsburgh, the offensive line had an 85% pass block win rate (second highest mark of the season) and a 22% pressure rate allowed (lowest Caleb Williams has faced all ...

The leaders of these two major corporations have made their positions on stock splits clear. The good news is that they don't need this catalyst to outperform the market. With major corporations, ...

The leaders of these two major corporations have made their positions on stock splits clear. The good news is that they don't need this catalyst to outperform the market. Waiting for these companies' ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min It's the first spinoff in ...

The BBC has announced that Jameela Jamil (The Good Place, She-Hulk) will guest star in The Split Up, a new six-part legal drama coming to BBC iPlayer and BBC One. Set in the charged world of ...

The automotive industry faces unprecedented change across four critical dimensions: evolving vehicle features, workforce transformation, sustainability demands, and shifting global production networks ...

U.S. aircraft carrier USS Gerald R. Ford - the world’s largest warship - anchored off the coast of Split, Croatia for a planned port visit on Tuesday, drawing crowds of residents and tourists who ...

In August, Zongertinib received FDA approval for previously treated HER2-mutant NSCLC. It now shows efficacy in first-line treatment, with a 77% objective response rate and 96% disease control rate.